Treatment for amphetamine withdrawal

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Shoptaw, Steven J ^a   Kao, Uyen ^a   Heinzerling, Keith ^a   Ling, Walter ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphetamine *adverse effects ; Clinical trials as topic; Dextroamphetamine adverse effects ; Dopamine uptake inhibitors *adverse effects ; Humans; Methamphetamine *adverse effects ; Substance withdrawal syndrome *therapy

Indexed keywords

AMINEPTINE; AMPHETAMINE; LORAZEPAM; MIRTAZAPINE; DEXAMPHETAMINE; DIBENZO[A,D]CYCLOHEPTENE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; METHAMPHETAMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; WITHDRAWAL SYNDROME; META ANALYSIS;

AMPHETAMINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEXTROAMPHETAMINE; DIBENZOCYCLOHEPTENES; DOPAMINE UPTAKE INHIBITORS; HUMANS; METHAMPHETAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 70349139307     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003021.pub2     Document Type: Review

References (32)

1. Cruickshank CC, Montebello ME, Dyer KR, Quigley A, Blaszczyk J, Tomkins S, Shand D. A placebo-controlled trial of mirtazapine for the management ofmethamphetamine withdrawal. Drug Alcohol Review 2008;27(3):326-333
2. Jittiwutikan J, Srisurapanont M, Jarusuraisin N. Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. Journal of the Medical Association of Thailand 1997;80(9):587-591 (Pubitemid 27513356)
3. Kongsakon R, Papadopoulos K, Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. International Clinical Psychopharmacology 2005;20(5):253-256. (Pubitemid 41192145)
4. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment. Australian and New Zealand Journal of Psychiatry 1999b;33:94-98. (Pubitemid 29121906)
5. Chan-Ob T, Kuntawongse N, Boonyanaruthee V. Bupropion for amphetamine withdrawal syndrome. Journal of the Medical Association of Thailand 2001;84(12):1763-1765
6. Cox D, Bowers R, McBride A. Reboxetine may be helpful in the treatment of amphetamine withdrawal. British Journal of Clinical Pharmacology 2004;58(1):100-101 (Pubitemid 38901474)
7. Gillin JC, Pulvirenti L, Withers N, Golshan S, Koob G. The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report. Biological Psychiatry 1994;35(11):843-849 (Pubitemid 24165008)
8. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005;100(9):1320-1329 (Pubitemid 41248073)
9. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual. Journal of Substance Abuse Treatment 2008a;35:334-342. [PUBMED: 18329221 Epub March 6 2008]
10. Cantwell B, McBride AJ. Self detoxification by amphetamine dependent patients: a pilot study. Drug and Alcohol Dependence 1998;49:157-163 (Pubitemid 28111902)
11. De Boer T. The pharmacologic profile of mirtazapine. Journal of Clinical Psychiatry 1996;57((supple 4)):19-25.
12. Derogatis LR. Brief symptom inventory administration, scoring, and proedures manual. Brief symptom inventory administration, scoring, and procedures manual. Minneapolis: The Psychological Corporation, National Computer Systems, Inc., 1993.
13. DSM-IV-TR. Diagnositic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000.
14. Gossop MR, Bradley BP, Brewis RK. Amphetamine withdrawal and sleep disturbance. Drug and Alcohol Dependence 1982;10(2-3):177-183
15. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, Maryland: National Institute of Mental Health, 1976.
16. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. The Cochrane Collaboration 2008: Available from www.cochrane-handbook.org.
17. Hofmann FG. A handbook on drug and alcohol abuse: the biomedical aspects. 2nd Edition. New York: Oxford University Press, 1983.
18. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008;27(3):309-317
19. McGregor C, Srisurapanont M, Mitchell A, Longo MC, Cahill S, White JM. Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. Journal of Substance Abuse Treatment 2008b;34(4):443-449 [PUBMED: 17629443 Epub 13 July 2007] (Pubitemid 351609289)
20. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harvard Review of Psychiatry 2005;13(3):141-154 (Pubitemid 40967247)
21. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. American Journal on Addictions 2004;13(3):248-255 (Pubitemid 38886472)
22. Pasic J, Russo JE, Ries RK, Roy-Byrne PP. Methamphetamine users in the psychiatric emergency services: A case-control study. Am J Drug Alcohol Abuse 2007;33(5):675-686 (Pubitemid 47463776)
23. Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. Journal of Substance Abuse Treatment 2002;23(2):145-150 (Pubitemid 36151695)
24. Rothman RB, Blough BE, Baumann MH. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. American Association of Pharmaceutical Scientists Journal 2007;9(1):E1-10.
25. Samanin R, Jori A, Bernasconi S, Morpugo E, Garattini S. Biochemical and pharmacological studies on amineptine (S 1694) and (+)-amphetamine in the rat. Journal of Pharmacy and Pharmacology 1977;29:555-558. (Pubitemid 8174834)
26. Schuckit MA, Daeppen J-B, Danko GP, et al. Clinical implications for four drugs of the DSM-IV distinction between substance dependence with and without a physiological component. American Journal of Psychiatry 1999;156:41-49
27. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychology Review 2007;17(3):275-297 (Pubitemid 47498174)
28. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. reliability, validity and factor structure of a measure. Australian and New Zealand Journal of Psychaitry 1999a;33:89-93. (Pubitemid 29121905)
29. United Nations Office on Drugs and Crime. World Drug Report 2008. www.unodc.org/documents/wdr/WDR-2008/WDR-2008-eng-web.pdf. Accessed on 9-07-08.
30. Voris J, Elder I, Sebastian P. A simple test of cocaine craving and related responses. Journal of Clinical Psychology 1991;47:320-323
31. Watson R, Hartmann E, Schildkraut JJ. Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion. American Journal of Psychiatry 1972;129(3):263-269
32. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine withdrawal. Cochrane Database of Systematic Reviews 2001, Issue 4.[Art. No.: CD003021. DOI: 10.1002/14651858.CD003021.pub2]